<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; gold</title>
	<atom:link href="http://www.tapanray.in/tag/gold/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>An El Dorado&#8230;But Not Without Responsible Pricing:The Cancer Segment in India</title>
		<link>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area</link>
		<comments>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/#comments</comments>
		<pubDate>Mon, 04 Feb 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[British]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cervical]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[female]]></category>
		<category><![CDATA[gold]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[male]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPP2012]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[oral]]></category>
		<category><![CDATA[ovarian]]></category>
		<category><![CDATA[ovary]]></category>
		<category><![CDATA[pancreatic]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[pot]]></category>
		<category><![CDATA[pots]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[urban]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1493</guid>
		<description><![CDATA[The affordability issue for cancer treatment has been the subject of a raging debate since quite some time, as the incidence of cancer is fast increasing across the world. Just for example a very recent report highlighted that cancer has now become the &#8230; <a href="http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Old is Always Not Gold&#8217;: The Saga of Uncertainty on the New Drug Policy Continues</title>
		<link>http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues</link>
		<comments>http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/#comments</comments>
		<pubDate>Mon, 19 Nov 2012 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Always]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Continues]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[gold]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[uncertainty]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1066</guid>
		<description><![CDATA[Along with the initiation of globalization process of India in 1991, many significant reform oriented steps are being taken by the Government for the pharmaceutical industry as its growth booster. In tandem with gradual reduction in the span of price &#8230; <a href="http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
